Clinical Trials Browser

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00703820 2021-08-10

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Phase 3 Completed

324 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01477606 2020-06-04

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Phase 2 Completed

451 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02560025 2020-05-05

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase 2 Completed

42 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01463046 2019-04-22

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Phase 1 Completed

29 enrolled

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02323607 2019-01-25

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

Phase 1 Completed

13 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01999413 2018-04-27

FAMYLY

Phase 2 Completed

30 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02198482 2018-02-28

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 2 Terminated

6 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Tazemetostat and Palbociclib With CPX-351for R/R AML

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

VAG-3+7-G

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms

A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

ATACC AML

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Venetoclax AML

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients

AML-DS-2025

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

MRD-positive AML Clinical Study

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Daunorubicin + Cytarabine + Venetoclax in de Novo AML

Revumenib in Combination With 7+3 + Midostaurin in AML

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

VA vs DA for Newly Diagnosed Hig-risk AML

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

MAGROLIC

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

AflacLL1901 (CHOA-AML)

Myechild01

PALG-AML1/2016

Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Protocol in Acute Myeloid Leukemia With FLT3-ITD

Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML

Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations

FAMYLY

Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)